Evaluation of recombinant activated protein C for severe sepsis at a tertiary academic medical center

PURPOSE: Early clinical trials of recombinant human activated protein C (rhAPC) for severe sepsis excluded patients at high risk of bleeding. Recent literature suggests bleeding rates are higher in clinical practice and may be associated with worsened outcomes. Our objective was to evaluate baseline...

Descripción completa

Detalles Bibliográficos
Autores principales: Anger, Kevin E, DeGrado, Jeremy R, Greenwood, Bonnie C, Cohen, Steven A, Szumita, Paul M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3678900/
https://www.ncbi.nlm.nih.gov/pubmed/23766652
http://dx.doi.org/10.2147/TCRM.S45412

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3678900/
https://www.ncbi.nlm.nih.gov/pubmed/23766652
http://dx.doi.org/10.2147/TCRM.S45412

Ejemplares similares